Cepheid Recalls Blood Culture MRSA Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid is recalling its blood culture-based MRSA test after some researchers reported getting inconclusive results, but investment analysts called the suspension of sales of the test "immaterial."

The Sunnyvale, Calif.-based molecular diagnostics firm sent a letter to customers this week saying it was suspending the sale of its Xpert MRSA/SA BC test after some researchers reported abnormally high invalid rates causing them to re-run the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.